Clinical trial · Observational
Vietnam Cryptococcal Retention in Care Study - Version 2.1
Vietnam Cryptococcal Retention in Care Study (CRICS) - Version 2.1
NCT03267407CI-TRIAL-00029498unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter prospective cohort evaluation of the implementation of a cryptococcal antigen (CrAg) screening program at selected outpatient HIV clinics (OPCs) and network laboratories in Vietnam.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cryptococcal Meningitis | — | UNRESOLVED | — |
| Cryptococcosis | — | UNRESOLVED | — |
| HIV/AIDS | — | UNRESOLVED | — |
| Mycosis Fungoides | Mycosis Fungoides | ONTOLOGY_EXACT | 0.98 |
| Mycosis; Opportunistic | — | UNRESOLVED | — |
| Opportunistic Infections, HIV Related | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Preemptive high-dose Fluconazole | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- CrAg(+) and CM(-)
- description
- (1) Patients with CrAg positive without meningitis results will receive preemptive high-dose fluconazole to prevent developing meningitis.
- interventionNames
- Other: Preemptive high-dose Fluconazole
- label
- CrAg(+) and CM(+)
- description
- (2) Patients with CrAg positive and meningitis results will receive standard treatment for cryptococcal meningitis, following national guidelines.
- interventionNames
- Other: Preemptive high-dose Fluconazole
- label
- CrAg(-)
- description
- (3) Patients with CrAg negative results will be managed as other HIV infected patients with the standard of care, following national guidelines.
- interventionNames
- Other: Preemptive high-dose Fluconazole
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged ≥ 18 years (having passed 18th birthday using Western calendar) * Confirmed HIV infection using National Testing Algorithm * CD4 ≤100 cells/μL * Able to provide written informed consent * Enrolled at and plan to receive ongoing outpatient care at one of the selected study OPCs Exclusion Criteria: * History of prior CM * Receipt of systemic antifungal medication for more than 4 consecutive weeks within the past 6 months * Receipt of ART for more than 4 consecutive weeks within the past year * For CrAg-positive patients only: Known to be currently pregnant or planning to become pregnant during the study period
References
Publications (0)
Data not yet available
No reference posted for this study.